IGF1R and c-met as therapeutic targets for colorectal cancer

被引:34
|
作者
Shali, Hajar [1 ,2 ]
Ahmadi, Majid [3 ,4 ]
Kafil, Hossein Samadi [5 ]
Dorosti, Abbasali [6 ]
Yousefi, Mehdi [3 ,4 ]
机构
[1] Tabriz Univ Med Sci, Liver & Gastrointestinal Dis Res Ctr, Tabriz, Iran
[2] Tabriz Univ Med Sci, Students Res Comm, Tabriz, Iran
[3] Tabriz Univ Med Sci, Immunol Res Ctr, Tabriz, Iran
[4] Tabriz Univ Med Sci, Sch Med, Dept Immunol, Tabriz, Iran
[5] Tabriz Univ Med Sci, Drug Appl Res Ctr, Tabriz, Iran
[6] Tabriz Univ Med Sci, Imam Reza Hosp, Sch Med, Dept Anesthesiol, Tabriz, Iran
关键词
Colorectal cancer; IGF1R; c-Met; Receptor tyrosine kinase; GROWTH-FACTOR-I; MONOCLONAL-ANTIBODY FIGITUMUMAB; FACTOR SIGNALING PATHWAY; FACTOR-BINDING-PROTEINS; INHIBITS TUMOR-GROWTH; FACTOR RECEPTOR; TYROSINE KINASE; COLON-CANCER; CARCINOMA CELLS; MEDIATED MIGRATION;
D O I
10.1016/j.biopha.2016.05.034
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The type 1 IGF receptor (IGF1R) and mesenchymal-epithelial transition (MET) are hetrodimeric and transmembrane receptor tyrosine kinases, which are frequently overexpressed by several tumor types, including colorectal cancer (CRC). These receptors bind to their specific ligands, insulin growth factors (IGFs) and hepatocyte growth factor (HGF), respectively, and promote signaling cascades which mediates many functions such as proliferation and protection against apoptosis, cell scattering, tumor cell motility, invasion and metastasis. In patients with metastatic colorectal cancer (mCRC), IGF1R and c-met expression confer resistance to cetuximab (monoclonal antibodies against EGFR). Therefore, the c-met and IGF1R are now an attractive novel target for anticancer therapy. In this review, we will describe correlation between two receptors and their activation effects in tumor cells, and finally introduce useful and available strategies for their targeting. (C) 2016 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:528 / 536
页数:9
相关论文
共 50 条
  • [1] Is There a Role for IGF1R and c-MET Pathways in Resistance to Cetuximab in Metastatic Colorectal Cancer?
    Inno, Alessandro
    Di Salvatore, Mariantonietta
    Cenci, Tonia
    Martini, Maurizio
    Orlandi, Armando
    Strippoli, Antonia
    Ferrara, Anna Maria
    Bagala, Cinzia
    Cassano, Alessandra
    Larocca, Luigi Maria
    Barone, Carlo
    CLINICAL COLORECTAL CANCER, 2011, 10 (04) : 325 - 332
  • [2] Met, IGF1R, and Other New Targets in Upper GI Malignancies
    Elizabeta C. Popa
    Manish A. Shah
    Current Treatment Options in Oncology, 2013, 14 : 321 - 336
  • [3] Met, IGF1R, and Other New Targets in Upper GI Malignancies
    Popa, Elizabeta C.
    Shah, Manish A.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2013, 14 (03) : 321 - 336
  • [4] The potential of monoclonal antibodies in cancer: established trastuzumab and cetuximab and promising targets IGF-1R and c-MET
    Bodmer, Alexandre
    Goetsch, Liliane
    Favet, Laurence
    Bailly, Christian
    Corvaia, Nathalie
    Dietrich, Pierre-Yves
    M S-MEDECINE SCIENCES, 2009, 25 (12): : 1090 - 1098
  • [5] Relation of the IGF/IGF1R system to autophagy in colitis and colorectal cancer
    Sipos, Ferenc
    Szekely, Hajnal
    Kis, Imre Daniel
    Tulassay, Zsolt
    Muzes, Gyorgyi
    WORLD JOURNAL OF GASTROENTEROLOGY, 2017, 23 (46) : 8109 - 8119
  • [6] Relation of the IGF/IGF1R system to autophagy in colitis and colorectal cancer
    Ferenc Sipos
    Hajnal Székely
    Imre Dániel Kis
    Zsolt Tulassay
    Gy?rgyi M?zes
    World Journal of Gastroenterology, 2017, 23 (46) : 8109 - 8119
  • [7] Biology and therapeutic targeting of IGF1R
    Soria, J. -C.
    REVUE DE PNEUMOLOGIE CLINIQUE, 2009, 65 : S7 - S10
  • [8] Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours
    Brigid C. Browne
    Alex J. Eustace
    Susan Kennedy
    Neil A. O’Brien
    Kasper Pedersen
    Martina S. J. McDermott
    Annemarie Larkin
    Jo Ballot
    Thamir Mahgoub
    Francesco Sclafani
    Stephen Madden
    John Kennedy
    Michael J. Duffy
    John Crown
    Norma O’Donovan
    Breast Cancer Research and Treatment, 2012, 136 : 717 - 727
  • [9] Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours
    Browne, Brigid C.
    Eustace, Alex J.
    Kennedy, Susan
    O'Brien, Neil A.
    Pedersen, Kasper
    McDermott, Martina S. J.
    Larkin, Annemarie
    Ballot, Jo
    Mahgoub, Thamir
    Sclafani, Francesco
    Madden, Stephen
    Kennedy, John
    Duffy, Michael J.
    Crown, John
    O'Donovan, Norma
    BREAST CANCER RESEARCH AND TREATMENT, 2012, 136 (03) : 717 - 727
  • [10] Erratum to: Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours
    Brigid C. Browne
    Alex J. Eustace
    Susan Kennedy
    Neil A. O’Brien
    Kasper Pedersen
    Martina S. J. McDermott
    Annemarie Larkin
    Jo Ballot
    Thamir Mahgoub
    Francesco Sclafani
    Stephen Madden
    John Kennedy
    Michael J. Duffy
    John Crown
    Norma O’Donovan
    Breast Cancer Research and Treatment, 2014, 148 : 697 - 697